Osiris Therapeutics - A trip to the underworld and back
Introduction¶
On November 2, 2017, the U.S. Securities and Exchange Commission filed charges against Osiris Therapeutics for fraudulent financial statements. Osiris Therapeutics settled the case by paying a penalty of USD 1.5 million.
The SEC alleges that Osiris Therapeutics routinely overstated company performance and issued fraudulent financial statements for a period of nearly two years. According to the SEC’s complaint, the company improperly recognized revenue using artificially inflated prices, backdated documents to recognize revenue in earlier periods, and prematurely recognized revenue upon delivery of products to be held on consignment. Osiris Therapeutics and its executives also allegedly used pricing data that they knew was false and attempted to book revenue on a fictitious transaction, among other accounting improprieties. (Source: SEC Press Release, highlights added)
The full SEC complaint can be downloaded here: Case 1:17-cv-03230-CCB